If you have been reading about human growth hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-25. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
== Technology overview == Point-of-care tests are simple medical tests that can be performed at the bedside. In many cases, the simplicity was not achievable until technology developed not only to make a test possible at all but then also to mask its complexity. For example, various kinds of urine test strips have been available for decades, but portable ultrasonography did not reach the stage of being advanced, affordable, and widespread until the 2000s and 2010s. Today, portable ultrasonography is often viewed as a "simple" test, but there was nothing simple about it until the more complex technology was available. Similarly, pulse oximetry can test arterial oxygen saturation in a quick, simple, noninvasive, affordable way today, but in earlier eras this required an intra-arterial needle puncture and a laboratory test; and rapid diagnostic tests such as malaria antigen detection tests or COVID-19 rapid tests that rely on a state of the art in immunology that did not exist until recent decades. Thus, over decades, testing continues to move toward the point of care more than it formerly had been. A recent survey in five countries (Australia, Belgium, the Netherlands, the UK and the US) indicates that general practitioners / family doctors would like to use more POCTs. The driving notion behind POCT is to bring the test conveniently and immediately to the patient. This increases the likelihood that the patient, physician, and care team will receive the results quicker, which allows for better immediate clinical management decisions to be made.
=== Constipation === Opioid-induced constipation (OIC) develops in 90 to 95% of people taking opioids long-term. Since tolerance to this problem does not generally develop, most people on long-term opioids need to take a laxative and/or enemas. Treatment of OIC is successional and dependent on severity. The first mode of treatment is non-pharmacological, and includes lifestyle modifications like increasing dietary fiber, fluid intake (around 1.5 L (51 US fl oz) per day), and physical activity. If non-pharmacological measures are ineffective, laxatives, including stool softeners (e.g., polyethylene glycol), bulk-forming laxatives (e.g., fiber supplements), stimulant laxatives (e.g., bisacodyl, senna), and/or enemas, may be used. A common laxative regimen for OIC is the combination of docusate and bisacodyl. Osmotic laxatives, including lactulose, polyethylene glycol, and milk of magnesia (magnesium hydroxide), as well as mineral oil (a lubricant laxative), are also commonly used for OIC. If laxatives are insufficiently effective (which is often the case), opioid formulations or regimens that include a peripherally-selective opioid antagonist, such as methylnaltrexone bromide, naloxegol, alvimopan, or naloxone (as in oxycodone/naloxone), may be tried. A 2018 (updated in 2022) Cochrane review found that the evidence was moderate for alvimopan, naloxone, or methylnaltrexone bromide but with increased risk of adverse events. Naloxone by mouth appears to be the most effective.
== Cross-Linked Enzyme Aggregates (CLEAs) == The use of cross-linked enzyme crystals (CLECs) as industrial biocatalysts was pioneered by Altus Biologics in the 1990s. CLECs proved to be significantly more stable to denaturation by heat, organic solvents and proteolysis than the corresponding soluble enzyme or lyophilized (freeze-dried) powder. CLECs are robust, highly active immobilized enzymes of controllable particle size, varying from 1 to 100 micrometer. Their operational stability and ease of recycling, coupled with their high catalyst and volumetric productivities, renders them ideally suited for industrial biotransformations. However, CLECs have an inherent disadvantage: enzyme crystallization is a laborious procedure requiring enzyme of high purity, which translates to prohibitively high costs. The more recently developed cross-linked enzyme aggregates (CLEAs), on the other hand, are produced by simple precipitation of the enzyme from aqueous solution, as physical aggregates of protein molecules, by the addition of salts, or water miscible organic solvents or non-ionic polymers. The physical aggregates are held together by covalent bonding without perturbation of their tertiary structure, that is without denaturation. Subsequent cross-linking of these physical aggregates renders them permanently insoluble while maintaining their pre-organized superstructure, and, hence their catalytic activity. This discovery led to the development of a new family of immobilized enzymes: cross-linked enzyme aggregates (CLEAs).
The basic principle of freeze drying is the removal of water by sublimation. Since the mass production of instant coffee began in post-WWII America, freeze-drying, which produces a flaky powder, has grown in popularity; it is more expensive than spray drying. Its long processing times may make it unsuitable for small-scale production. In this process, coffee extract is frozen, rapidly to prevent the formation of larger ice crystals, then milled into small granules, which are sifted to ensure a uniform size and added to an industrial freeze dryer. The previously frozen water expands the coffee granules to ten times their previous volume through sublimation. The freeze-dried granules are then removed from the chamber and packaged for sale.
US–South African relations took an unexpected turn with Ronald Reagan's electoral victory in the 1980 US presidential elections. Reagan's tough anti-communist record and rhetoric was greeted with cautious optimism by Pretoria; during his election campaign he'd described the geopolitical situation in southern Africa as "a Russian weapon" aimed at the US. President Reagan and his Assistant Secretary of State for African Affairs Chester Crocker adopted a policy of constructive engagement with the Botha government, restored military attachés to the US embassy in South Africa, and permitted SADF officers to receive technical training in the US. They believed that pressure tactics against South Africa would be contrary to US regional goals, namely countering Soviet and Cuban influence. In a private memo addressed to the South African foreign minister, Crocker and his supervisor Alexander Haig declared that "we [the US] share your view that Namibia must not be turned over to the Soviets and their allies. A Russian flag in Windhoek is as unacceptable to us as it is to you". Washington also ended its condemnation of SADF cross-border raids, which was perceived as tacit support for the latter's actions in Angola and elsewhere. This had the effect of encouraging Botha to proceed with larger and increasingly more ambitious operations against PLAN. Between 1980 and 1982 South African ground forces invaded Angola three times to destroy the well-entrenched PLAN logistical infrastructure near the border region.
Sources: en.wikipedia.org
mobilome The complete set of mobile genetic elements within a particular genome, cell, species, or other taxon, including all transposons, plasmids, prophages, and other self-splicing nucleic acid molecules.
The Romanian Armed Forces consist of land, air, and naval forces led by a Commander-in-chief under the supervision of the Ministry of National Defence, and by the president as the Supreme Commander during wartime. The Armed Forces consist of approximately 55,000 reservists and 71,500 active military personnel—35,800 for land, 10,700 for air, 6,600 for naval forces, and 16,500 in other fields. Total defence spending in 2023 accounted for 2.44% of total national GDP, or approximately US$8.48 billion, with a total of $9 billion intended to be spent until 2026 for modernisation and acquisition of new equipment. Conscription stopped in 2007, when Romania switched to a volunteer army. The Air Force operates F-16AM/BM MLU fighters, C-27J Spartan and C-130 Hercules transport aircraft, as well as IAR 330 and IAR 316 helicopters. A procurement programme for F-35 fifth-generation fighters is also currently being carried out. The Naval Forces operate three frigates, of which two are Type 22 frigates acquired from the British Royal Navy, as well as four corvettes. The River Flotilla operates Mihail Kogălniceanu and Smârdan-class river monitors. Romania contributed troops to the international coalition in Afghanistan beginning in 2002, with a peak deployment of 1,600 troops in 2010 (which was the 4th largest contribution according to the US). Its combat mission in the country concluded in 2014. Romanian troops participated in the occupation of Iraq, reaching a peak of 730 soldiers before being slowly drawn down to 350 soldiers.
=== Preimplantation genetic diagnosis === Embryos produced using in vitro fertilization may be genetically tested for HD using preimplantation genetic diagnosis. This technique, where one or two cells are extracted from a typically 4- to 8-cell embryo and then tested for the genetic abnormality, can then be used to ensure embryos affected with HD genes are not implanted, so any offspring will not inherit the disease. Some forms of preimplantation genetic diagnosis—non-disclosure or exclusion testing—allow at-risk people to have HD-free offspring without revealing their own parental genotype, giving no information about whether they themselves are destined to develop HD. In exclusion testing, the embryo's DNA is compared with that of the parents and grandparents to avoid inheritance of the chromosomal region containing the HD gene from the affected grandparent. In nondisclosure testing, only disease-free embryos are replaced in the uterus while the parental genotype and hence parental risk for HD are never disclosed.
=== Safer supply === Safer supply programs prescribe medications (including stimulants, opioids, and benzodiazepines) to people at high risk of overdose. This is meant to provide a safer alternative to an illegal drug supply that contains high levels of fentanyl and other dangerous chemicals. The structure of such programs is more flexible than opioid agonist therapy. The drugs dispensed by these programs can result in intoxication, unlike methadone or buprenorphine. Safer supply projects exist in a number of Canadian cities. Critics of these programs point to the risk of drug diversion and argue that patients should be encouraged to enter drug rehabilitation programs instead of being given drugs.
Bronzers are a temporary sunless tanning or bronzing option. These come in powders, sprays, mousse, gels, lotions and moisturizers. Once applied, they create a tan that can easily be removed with soap and water. Like make-up, these products tint or stain a person's skin only until they are washed off. They are often used for "one-day" only tans, or to complement a DHA-based sunless tan. Many formulations are available, and some have limited sweat or light water resistance. Walnut oil extract, jojoba extract, and caramel are ingredients frequently used in temporary bronzers. If bronzer is applied under clothing, or where fabric and skin edges meet, most will create some light but visible rub-off. Dark clothing prevents the rub-off from being noticeable. While these products are much safer than tanning beds, the color produced can sometimes look orangey and splotchy if applied incorrectly. A recent trend is that of lotions or moisturizers containing a gradual tanning agent. A slight increase in color is usually observable after the first use, but color will continue to darken the more frequently the product is used. Just as with the term "sunless tanner", the term "bronzer" is likewise not defined by law, or by regulations enforced by the FDA. What is defined and regulated is the color additive DHA, or dihydroxyacetone. (Note that the "color additive" dihydroxyacetone is itself colorless.) Many of these bronzers contain allergens such as benzyl alcohol, tocopherol (vitamin E), and fragrances.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.